Protein kinase C as a tumor suppressor
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Protein kinase C (PKC) has historically been considered an oncoprotein. This stems in large part from the discovery in the early 1980s that PKC is directly activated by tumor-promoting phorbol esters. Yet three decades of clinical trials using PKC inhibitors in cancer therapies not only failed, but in some cases worsened patient outcome. Why has targeting PKC in cancer eluded successful therapies? Recent studies looking at the disease for insight provide an explanation: cancer-associated mutations in PKC are generally loss-of-function (LOF), supporting an unexpected function as tumor suppressors. And, contrasting with LOF mutations in cancer, germline mutations that enhance the activity of some PKC isozymes are associated with degenerative diseases such as Alzheimer's disease. This review provides a background on the diverse mechanisms that ensure PKC is only active when, where, and for the appropriate duration needed and summarizes recent findings converging on a paradigm reversal: PKC family members generally function by suppressing, rather than promoting, survival signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., & Nishizuka, Y. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34459-4 · Cited by 4,725 · cited 1×
“Their synthesis of phorbol 12,13-dibutyrate (PDBu) not only allowed the identification of PKC as a major receptor for phorbol esters [44], but to this day remains one of the most commonly used tools to modulate signaling pathways in cells.”
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169 · cited 2×
“with improved survival in hormone-insensitive, but not hormonesensitive, breast cancers [108].”
A Human Interactome in Three Quantitative Dimensions Organized by Stoichiometries and Abundances
Hein, M. Y., Hubner, N. C., Poser, I., Cox, J., Nagaraj, N., Toyoda, Y., Gak, I. A., Weisswange, I., Mansfeld, J., Buchholz, F., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.053 · Cited by 1,270
Protein kinase C and other diacylglycerol effectors in cancer
Griner, E. M., & Kazanietz, M. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2110 · Cited by 978 · cited 2×
“PKCδ, which has roles both in survival and apoptotic pathways [38,101], has been reported to promote tumor progression in pancreatic cancer [102], and mice deficient in this isozyme have an increased incidence of lung tumors [103].”
Gao, T., Furnari, F., & Newton, A. C. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.008 · Cited by 906
Self-citationProtein kinase C and cancer: what we know and what we do not
Garg, R., Benedetti, L. G., Abera, M. B., Wang, H., Abba, M., & Kazanietz, M. G. (2014) · Oncogene · doi:10.1038/onc.2013.524 · Cited by 303
K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling
Wang, M.-T., Holderfield, M., Galeas, J., Delrosario, R., To, M. D., Balmain, A., & McCormick, F. (2015) · Cell · doi:10.1016/j.cell.2015.10.041 · Cited by 196
Pongracz, J., Clark, P., Neoptolemos, J. P., & Lord, J. M. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610107 · Cited by 137
Gould, C. M., Kannan, N., Taylor, S. S., & Newton, A. C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808436200 · Cited by 113 · cited 2×
“Notably, mTOR inhibitors [125] and Hsp90 inhibitors [126], which are currently in use in the clinic, prevent processing of PKC [12,13].”
Self-citation
Cited by
Equivocal, explicit and emergent actions of PKC isoforms in cancer
Parker, P. J., Brown, S. J., Calleja, V., Chakravarty, P., Cobbaut, M., Linch, M., Marshall, J. J. T., Martini, S., McDonald, N. Q., Soliman, T., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00310-4 · Cited by 65
Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer
Sadeghi, M. M., Salama, M. F., & Hannun, Y. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115527 · Cited by 31
COL1A2 is a TBX3 target that mediates its impact on fibrosarcoma and chondrosarcoma cell migration
Omar, R., Cooper, A., Maranyane, H. M., Zerbini, L., & Prince, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.06.004 · Cited by 21
Metadata
- Authors
- Newton, A. C.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 48
- Pages
- 18-26
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2610191231
- Cited by
- 105
- References
- 12
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.